Increase of interferon-γ-inducible CXC chemokine CXCL10 serum levels in patients with active Graves' disease, and modulation by methimazole therapy
Increase of interferon-γ-inducible CXC chemokine CXCL10 serum levels in patients with active Graves' disease, and modulation by methimazole therapy
复制标题
DOI：
10.1111/j.1365-2265.2006.02447.x
复制
发表时间：
2006-02-01
影响因子：
3.2
通讯作者：
Serio, M
中科院分区：
文献类型：
--
作者：
Antonelli, A;Rotondi, M;Serio, M
背景CXCL 10在Graves病（GD）和自身免疫性甲状腺炎（AT）的发病初期起重要作用;然而，迄今为止，尚未对GD患者血清CXCL 10水平（sCXCL 10）与甲状腺功能和治疗的关系进行评估。目的评估sCXCL 10在GD中的作用。设计横断面。103例GD，164例AT，非毒性结节性甲状腺肿（NTMNG）20例，毒性结节性甲状腺肿（TNG）16例，健康对照组70例（年龄和性别匹配）。测量我们测量了患者和对照中的sCXCL 10，结果GD和AT患者的sCXCL 10平均值相当，（122 +/- 81和133 +/- 102 pg/ml）并且显著高于（P < 0.01）对照或NTMNG患者（分别为73 +/- 32和76 +/- 25 pg/ml）。甲状腺功能亢进性GD的sCXCL 10显著高于甲状腺功能正常或甲状腺功能减退性GD（分别为145 +/- 92、107 +/- 56和105 +/- 46 pg/ml; P = 0.01）。甲状腺功能亢进的GD患者未经治疗的sCXCL 10高于甲巯咪唑（MMI）治疗的甲状腺功能亢进或甲状腺功能正常的GD患者（分别为166 +/- 125，124 +/- 41和94 +/- 35 pg/ml; P = 0.006）。在新诊断的未经治疗的甲状腺功能亢进GD患者中观察到的sCXCL 10水平与既往MMI疗程后甲状腺功能亢进复发的未经治疗患者相当（分别为176 +/- 125，155 +/- 97 pg/ml）。GD患者sCXCL 10水平与AT相似，但高于TNG患者或对照组（年龄和性别均匹配）（分别为144 ± 81、149 ± 114、101 ± 27和86 ± 44 pg/ml; P = 0.02）。治疗后GD患者sCXCL 10的降低可能与MMI的免疫调节作用有关。
Background CXCL10 plays an important role in the initial phases of Graves' disease (GD) and autoimmune thyroiditis (AT); however, until now, CXCL10 serum levels (sCXCL10) in patients with GD have never been evaluated in relation to thyroid function and treatment.Objective To evaluate sCXCL10 in GD.Design Cross-sectional.Patients One hundred and three GD, 164 AT, 20 nontoxic multinodular goitre (NTMNG), 16 toxic nodular goitre (TNG) patients and 70 healthy controls (age- and sex-matched).Measurements We measured sCXCL10 in patients and controls, to relate this parameter to the clinical phenotype.Results Mean sCXCL10 in GD and AT patients were comparable (122 +/- 81 and 133 +/- 102 pg/ml) and significantly higher (P < 0.01) than in controls or NTMNG patients (73 +/- 32 and 76 +/- 25 pg/ml, respectively). Hyperthyroid GD had significantly higher sCXCL10 than euthyroid or hypothyroid GD (145 +/- 92, 107 +/- 56 and 105 +/- 46 pg/ml, respectively; P = 0.01). GD patients with untreated hyperthyroidism had higher sCXCL10 than hyperthyroid or euthyroid GD patients under methimazole (MMI) treatment (166 +/- 125, 124 +/- 41 and 94 +/- 35 pg/ml, respectively; P = 0.006). Comparable sCXCL10 levels were observed in newly diagnosed untreated hyperthyroid GD patients with respect to untreated patients with relapse of hyperthyroidism after a previous MMI course (176 +/- 125, 155 +/- 97 pg/ml, respectively). GD had similar sCXCL10 to AT and higher than TNG patients or controls (all age- and sex-matched) (144 +/- 81, 149 +/- 114, 101 +/- 27 and 86 +/- 44 pg/ml, respectively; P = 0.02).Conclusions sCXCL10 is associated with the active phase of GD in both newly diagnosed and relapsing hyperthyroid patients. The reduction in sCXCL10 in treated patients with GD may be related to the immunomodulatory effects of MMI.